Nagymihály Mariann, Herczegfalvi Agnes, Tímár László, Karcagi Veronika
Országos Környezet-egészségügyi Intézet, Molekuláris Genetikai és Diagnosztikai Osztály, Budapest.
Ideggyogy Sz. 2009 Nov 30;62(11-12):390-7.
Spinal muscular atrophy (SMA) is one of the most common autosomal recessive diseases, affecting approximately one in 10,000 live births and with a carrier frequency of approximately one in 35. The disease is caused by a deficiency of the ubiquitous protein survival of motor neuron (SMN), which is encoded by the SMN1 and SMN2 genes. Due to a single nucleotide polymorphism in exon 7, SMN2 produces less full-length transcript than SMN1 and cannot prevent neuronal cell death at physiologic gene dosages. On the other hand, the copy number of SMN2 affects the amount of SMN protein produced and the severity of the SMA phenotype. SMN gene dosage analysis can determine the copy number of SMN1 to detect carriers and patients heterozygous for the absence of SMN1 exon 7. This study provides copy number estimation of SMN1 gene by real-time PCR technique in 56 SMA type I., II., III. patients, 159 parents and healthy relatives and in 152 undefined SMA patients. Among the family members, 91 carriers have been detected and in 56 patients homozygous deletion of SMN1 exon 7 has been confirmed. Moreover, in 12 patients compound heterozygosity of SMN1 exon 7 mutation has been detected, thus providing the possible diagnosis of SMA. In 94 patients, copy number of SMN2 has also been evaluated and a good correlation has been found with the phenotype of the disease. Due to the genetic complexity and the high carrier frequency, accurate risk assessment and genetic counselling are particularly important for the families. These new results provide improvement of the diagnostic service in SMA in Hungary with focus on proper genetic counselling and possible enrolment of the patients in future therapeutic interventions.
脊髓性肌萎缩症(SMA)是最常见的常染色体隐性疾病之一,发病率约为1/10000活产儿,携带者频率约为1/35。该疾病由普遍存在的运动神经元存活蛋白(SMN)缺乏引起,SMN由SMN1和SMN2基因编码。由于外显子7中的单核苷酸多态性,SMN2产生的全长转录本比SMN1少,并且在生理基因剂量下无法预防神经元细胞死亡。另一方面,SMN2的拷贝数影响所产生的SMN蛋白的量以及SMA表型的严重程度。SMN基因剂量分析可以确定SMN1的拷贝数,以检测缺乏SMN1外显子7的携带者和杂合子患者。本研究通过实时PCR技术对56例I型、II型、III型SMA患者、159名父母和健康亲属以及152例未明确的SMA患者进行了SMN1基因的拷贝数估计。在家庭成员中,已检测到91名携带者,56例患者中已证实存在SMN1外显子7的纯合缺失。此外,在12例患者中检测到SMN1外显子7突变的复合杂合性,从而提供了SMA的可能诊断。在94例患者中,还评估了SMN2的拷贝数,并发现与疾病表型有良好的相关性。由于遗传复杂性和高携带者频率,准确的风险评估和遗传咨询对家庭尤为重要。这些新结果改善了匈牙利SMA的诊断服务,重点是适当的遗传咨询以及未来治疗干预中患者的可能入组。